Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia

Adriana Branchi, Angelo Rovellini, Domenico Sommariva

Research output: Contribution to journalArticle

Abstract

Our study goal was to determine whether two hypolipidemic drugs, each with a different mechanism of action, have different effects on serum levels of high-density lipoprotein (HDL) subpopulations, as defined by the presence of apolipoprotein (apo) A-I (Lp A-I) and of both apo A-I and A-II (Lp A-I:A-II). Nineteen patients with primary hypercholesterolemia were treated for 3 months with simvastatin 20 mg once daily and 19 patients were treated with sustained-release bezafibrate 400 mg/d. Seventeen patients following a stable low-cholesterol, low-fat diet served as a reference group. In both the diet-only and simvastatin groups, no significant change in HDL-cholesterol (HDL-C), apo A-I, apo A-II, Lp A-I, and Lp A-I:A-II occurred; in the bezafibrate group, HDL-C increased by 10%, apo A-I by 15%, and apo A-II by 43%. Lp A-I decreased by 15% and Lp A-I:A-II increased by 33% in the bezafibrate group. The relevance to the risk of coronary heart disease of the decrease of Lp A-I after bezafibrate therapy is uncertain, although Lp A-I - but not Lp A-I:A-II - has been suggested to account for the protective role of HDL.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalCurrent Therapeutic Research
Volume57
Issue number1
DOIs
Publication statusPublished - 1996

Fingerprint

Bezafibrate
Simvastatin
Apolipoproteins
Apolipoprotein A-I
HDL Lipoproteins
Hypercholesterolemia
Apolipoprotein A-II
Hypolipidemic Agents
Fat-Restricted Diet
HDL Cholesterol
Coronary Disease
Cholesterol
Diet
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b1125bf15c2c41e68dffcc6a6d2b891e,
title = "Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia",
abstract = "Our study goal was to determine whether two hypolipidemic drugs, each with a different mechanism of action, have different effects on serum levels of high-density lipoprotein (HDL) subpopulations, as defined by the presence of apolipoprotein (apo) A-I (Lp A-I) and of both apo A-I and A-II (Lp A-I:A-II). Nineteen patients with primary hypercholesterolemia were treated for 3 months with simvastatin 20 mg once daily and 19 patients were treated with sustained-release bezafibrate 400 mg/d. Seventeen patients following a stable low-cholesterol, low-fat diet served as a reference group. In both the diet-only and simvastatin groups, no significant change in HDL-cholesterol (HDL-C), apo A-I, apo A-II, Lp A-I, and Lp A-I:A-II occurred; in the bezafibrate group, HDL-C increased by 10{\%}, apo A-I by 15{\%}, and apo A-II by 43{\%}. Lp A-I decreased by 15{\%} and Lp A-I:A-II increased by 33{\%} in the bezafibrate group. The relevance to the risk of coronary heart disease of the decrease of Lp A-I after bezafibrate therapy is uncertain, although Lp A-I - but not Lp A-I:A-II - has been suggested to account for the protective role of HDL.",
author = "Adriana Branchi and Angelo Rovellini and Domenico Sommariva",
year = "1996",
doi = "10.1016/S0011-393X(96)80026-9",
language = "English",
volume = "57",
pages = "26--32",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia

AU - Branchi, Adriana

AU - Rovellini, Angelo

AU - Sommariva, Domenico

PY - 1996

Y1 - 1996

N2 - Our study goal was to determine whether two hypolipidemic drugs, each with a different mechanism of action, have different effects on serum levels of high-density lipoprotein (HDL) subpopulations, as defined by the presence of apolipoprotein (apo) A-I (Lp A-I) and of both apo A-I and A-II (Lp A-I:A-II). Nineteen patients with primary hypercholesterolemia were treated for 3 months with simvastatin 20 mg once daily and 19 patients were treated with sustained-release bezafibrate 400 mg/d. Seventeen patients following a stable low-cholesterol, low-fat diet served as a reference group. In both the diet-only and simvastatin groups, no significant change in HDL-cholesterol (HDL-C), apo A-I, apo A-II, Lp A-I, and Lp A-I:A-II occurred; in the bezafibrate group, HDL-C increased by 10%, apo A-I by 15%, and apo A-II by 43%. Lp A-I decreased by 15% and Lp A-I:A-II increased by 33% in the bezafibrate group. The relevance to the risk of coronary heart disease of the decrease of Lp A-I after bezafibrate therapy is uncertain, although Lp A-I - but not Lp A-I:A-II - has been suggested to account for the protective role of HDL.

AB - Our study goal was to determine whether two hypolipidemic drugs, each with a different mechanism of action, have different effects on serum levels of high-density lipoprotein (HDL) subpopulations, as defined by the presence of apolipoprotein (apo) A-I (Lp A-I) and of both apo A-I and A-II (Lp A-I:A-II). Nineteen patients with primary hypercholesterolemia were treated for 3 months with simvastatin 20 mg once daily and 19 patients were treated with sustained-release bezafibrate 400 mg/d. Seventeen patients following a stable low-cholesterol, low-fat diet served as a reference group. In both the diet-only and simvastatin groups, no significant change in HDL-cholesterol (HDL-C), apo A-I, apo A-II, Lp A-I, and Lp A-I:A-II occurred; in the bezafibrate group, HDL-C increased by 10%, apo A-I by 15%, and apo A-II by 43%. Lp A-I decreased by 15% and Lp A-I:A-II increased by 33% in the bezafibrate group. The relevance to the risk of coronary heart disease of the decrease of Lp A-I after bezafibrate therapy is uncertain, although Lp A-I - but not Lp A-I:A-II - has been suggested to account for the protective role of HDL.

UR - http://www.scopus.com/inward/record.url?scp=0030069434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030069434&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(96)80026-9

DO - 10.1016/S0011-393X(96)80026-9

M3 - Article

AN - SCOPUS:0030069434

VL - 57

SP - 26

EP - 32

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 1

ER -